Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path Initiative-Reference-Cited by-同舟云学术

Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path Initiative

Published:2009-09 Issue:3 Volume:158 Page:317-326
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Piccini Jonathan P.,Whellan David J.,Berridge Brian R.,Finkle John K.,Pettit Syril D.,Stockbridge Norman,Valentin Jean-Pierre,Vargas Hugo M.,Krucoff Mitchell W.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference50 articles.

1. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceuticals markets — 1960 to 1999;Fung;Drug Inf J,2001

2. Introduction;Stephens,2004

3. Astemizole: voluntary withdrawal: Janssen, USA,1999

4. Withdrawal of troglitazone and cisapride;Henney;JAMA,2000

5. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction;The Cardiac Arrhythmia Suppression Trial (CAST) Investigators;N Engl J Med,1989

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Commercial achievements resulting from multi-organ-on-a-chip applications;Human Organs-On-a-chip;2024

2. Heart-on-a-chip systems: disease modeling and drug screening applications;Lab on a Chip;2024

3. Advances in organ‐on‐a‐chip for the treatment of cardiovascular diseases;MedComm – Biomaterials and Applications;2023-11-07

4. Applications of piperazine scaffold in drug design;Privileged Scaffolds in Drug Discovery;2023

5. Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes;Journal of Visualized Experiments;2022-08-09